23%

Improvement in Medication Adherence Rate

33%

Capture of Quality of Life Score

47%

Reduction in EEG Abnormality Rate

44%

Increase in Neurologist Consultation Rate

This drug effectiveness analytics dashboard compares healthcare utilization and costs for long acting and short acting antiepileptic drug monotherapy. R&D professionals, scientists, and healthcare leaders use it to support pharma business decisions with concrete findings. Infocepts built it on MicroStrategy for life sciences teams.

The dashboard puts utilization and cost reports side by side, so teams can compare the two dosing formats in one place. Infocepts structured the underlying data for analysis through business analytics services.

Explore more in our Life Sciences section, or see the medication adherence and therapy insights and disease monitoring dashboards.

Want a similar analytics view for your pharma team? Talk to our team about what to track and how to build it.

Frequently asked questions

It compares healthcare utilization, costs, and patient outcomes across treatment options, such as long acting versus short acting antiepileptic drug monotherapy, to give R&D and pharma teams evidence rather than assumption.

Utilization and cost patterns often differ meaningfully between dosing formats; comparing them directly surfaces which option delivers better outcomes per healthcare dollar spent.

R&D professionals, scientists, and healthcare leaders making decisions about treatment positioning, market access, or further drug development investment.

Business and clinical decisions about which therapy formats to prioritize, based on concrete utilization and outcome data rather than published trial results alone.

No. It complements trial data with real world utilization and cost evidence, which trials are not designed to capture at this level of operational detail.

By structuring healthcare utilization and outcomes data into a BI platform through Business Analytics services, informed by Life Sciences industry work.